Please use this identifier to cite or link to this item: https://doi.org/10.1186/s12943-017-0596-9
Title: Epigenetics in cancer stem cells
Authors: Toh, T.B 
Lim, J.J 
Chow, E.K.-H 
Keywords: beta catenin
DNA
DNA methyltransferase
histone
histone deacetylase
histone demethylase
histone methyltransferase
Notch receptor
sonic hedgehog protein
Wnt protein
antineoplastic agent
DNA (cytosine 5) methyltransferase
histone
cancer growth
cancer stem cell
carcinogenesis
DNA methylation
drug resistance
epigenetics
epithelial mesenchymal transition
genetic regulation
histone acetylation
histone demethylation
histone methylation
human
metastasis
nonhuman
Review
signal transduction
acetylation
animal
antagonists and inhibitors
cancer stem cell
drug effects
genetic epigenesis
genetics
metabolism
methylation
Neoplasms
pathology
procedures
Acetylation
Animals
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
DNA (Cytosine-5-)-Methyltransferase
DNA Methylation
Drug Resistance, Neoplasm
Epigenesis, Genetic
Epigenomics
Histones
Humans
Methylation
Neoplasm Metastasis
Neoplasms
Neoplastic Stem Cells
Signal Transduction
Issue Date: 2017
Citation: Toh, T.B, Lim, J.J, Chow, E.K.-H (2017). Epigenetics in cancer stem cells. Molecular Cancer 16 (1) : 29. ScholarBank@NUS Repository. https://doi.org/10.1186/s12943-017-0596-9
Rights: Attribution 4.0 International
Abstract: Compelling evidence have demonstrated that bulk tumors can arise from a unique subset of cells commonly termed "cancer stem cells" that has been proposed to be a strong driving force of tumorigenesis and a key mechanism of therapeutic resistance. Recent advances in epigenomics have illuminated key mechanisms by which epigenetic regulation contribute to cancer progression. In this review, we present a discussion of how deregulation of various epigenetic pathways can contribute to cancer initiation and tumorigenesis, particularly with respect to maintenance and survival of cancer stem cells. This information, together with several promising clinical and preclinical trials of epigenetic modulating drugs, offer new possibilities for targeting cancer stem cells as well as improving cancer therapy overall. © 2017 The Author(s).
Source Title: Molecular Cancer
URI: https://scholarbank.nus.edu.sg/handle/10635/181300
ISSN: 14764598
DOI: 10.1186/s12943-017-0596-9
Rights: Attribution 4.0 International
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1186_s12943-017-0596-9.pdf866.57 kBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons